Prasad S. Adusumilli | MD FACS FCCP, of MSKCC

Dr Prasad S. Adusumilli, MD FACS FCCP, is Deputy Chief, Thoracic Service; Co-Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center at the Memorial Sloan Kettering Cancer Center in New York.

Dr Adusimilli is a world-renowned thoracic surgeon with expertise in the diagnosis and treatment of cancers in the chest — lung cancer, esophageal cancer, mesothelioma, thymoma, mediastinal and chest wall tumors, and cancers metastatic to lung and pleura.

Rebecca Auer | Ottawa Hospital

Dr Rebecca Auer, MD MSc FRCSC, Associate Professor, Department of Surgery and Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine University of Ottawa; Surgical Oncologist, The Ottawa Hospital; Tier 2 Clinical Research Chair in Perioperative Cancer Therapeutics University of Ottawa.

As a Surgeon-Scientist, Dr Auer heads a research laboratory and is the principle investigator in related clinical trials. Her translational research program focuses on understanding the promotion of metastatic disease in the perioperative period, following surgical stress. In particular she is studying novel perioperative cancer therapies, including oncolytic viruses, cancer vaccines and targeted therapies, which inhibit the formation of metastases postoperatively.

Tanios Bekaii-Saab | Mayo Clinic

Dr. Tanios Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts. Dr. Bekaii-Saab is a Professor of Medicine at the Mayo Clinic College of Medicine and Science, Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, Medical Director of the Cancer Clinical Research Office, and Vice Chair and Section Chief for Medical Oncology for the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona.

Yuman Fong, MD |  Chair of the Department of Surgery at City of Hope

Dr Yuman Fong, MD is Chair of the Department of Surgery at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases based near Los Angeles.

Dr Fong is a world-renowned cancer researcher, physician and surgeon whose clinical work has focused on OV for over 30 years. He is the inventor of OV CF33.

Yelena Janjigian | Memorial Sloan Kettering Cancer Center

Dr. Yelena Janjigian is a medical oncologist at the Memorial Sloan Kettering Cancer Center, the oldest and largest private cancer centre in the US. Dr. Janjigian specializes in the treatment of malignancies of the gastrointestinal tract, including esophagus and stomach cancers. Her research focuses on the development of new treatments for patients with esophagus and stomach cancers, and is particularly interested in finding ways to select the best treatments for persons with cancer based on the molecular characteristics of their tumor specimens. Dr. Janjigian runs clinical and translational studies designed to develop a better prevention, early diagnosis, staging, and treatment strategies. She is the Principal Investigator on a number of clinical trials at Memorial Sloan Kettering. Dr. Janjigian received her doctorate in medicne from New York University School of Medicine. Dr. Janjigian holds board certifications for internal medicine and medical oncology.

Pravin Kaumaya | Ohio State University

Pravin Kaumaya is Professor of Medicine in Department of Ob/Gyn at the OSU Wexner Medical Center and the James Comprehensive Cancer Center. Dr Kaumaya is internationally recognized as an expert in the fields of vaccine research with emphasis on peptide vaccines for cancer, viral diseases as well as peptide therapy for autoimmune diseases. He conducts research in the areas of tumor immunology, mechanisms of tumor cell-immune cell interactions, and immune mechanisms. He is an inventor on several issued and pending patents for Peptide Vaccines and Therapeutic Technologies. He has lectured worldwide and has published over 130 peer-reviewed articles in major scientific journals.

Neil Segal | Memorial Sloan Kettering Cancer Center

Dr Segal is an oncologist at the Memorial Sloan Kettering Cancer Center, the oldest and largest private cancer centre in the US. His research interests focus on the development of new therapies and more specifically, ways to use the immune system to treat cancer. This parallels the approach taken with Imugene’s HER-Vaxx vaccine, which aims to activate the patient’s immune system to produce its own antibodies. Dr Segal has further clinical expertise in colorectal, pancreatic, bile duct and other gastrointestinal cancers. He holds a Doctorate of Medicine and Philosophy from University of the Witwatersrand in South Africa.

Peter Schmid | Queen Mary University, London

Professor Schmid is Chair of Cancer Medicine at the prestigious Barts Cancer Institute at Queen Mary University London. He is also Clinical Director of the Breast Cancer Centre at the St. Bartholomew Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital. He leads the Centre of Experimental Cancer Medicine at Barts Cancer Institute and the Barts/Brighton Experimental Cancer Medicine Centre.

Prof Schmid’s specialist cancer interests are breast and lung cancer, cancer immune therapy and early drug development.

He has successfully led more than 20 national and international academic clinical studies and is a member of several national and international cancer organizations and research groups. He has authored or co-authored 165 publications and published a book on the management of bone metastases currently in its third edition.

Josep Tabernero | President of ESMO

Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain, and he is currently Head of the Medical Oncology Department at the Vall d’Hebron University Hospital and Director of the Vall d’Hebron Institute of Oncology (VHIO). He is Principal Investigator of several Phase I pharmacodynamic studies and translational projects with tumour-directed targeted therapies and immune therapies.

Josep is also a member of the American Association for Cancer Research (AACR), and the American Society of Clinical Oncology (ASCO).